O

Orchestra Biomed Holdings Inc
NASDAQ:OBIO

Watchlist Manager
Orchestra Biomed Holdings Inc
NASDAQ:OBIO
Watchlist
Price: 4.04 USD -2.18%
Market Cap: $228.1m

Operating Margin

-2 669.9%
Current
Declining
by 686.9%
vs 3-y average of -1 983%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-2 669.9%
=
Operating Income
$-75.2m
/
Revenue
$2.8m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-2 669.9%
=
Operating Income
$-75.2m
/
Revenue
$2.8m

Peer Comparison

Country Company Market Cap Operating
Margin
US
Orchestra Biomed Holdings Inc
NASDAQ:OBIO
233.2m USD
Loading...
US
Intuitive Surgical Inc
NASDAQ:ISRG
188.5B USD
Loading...
US
Abbott Laboratories
NYSE:ABT
185.8B USD
Loading...
US
Boston Scientific Corp
NYSE:BSX
136.5B USD
Loading...
US
Stryker Corp
NYSE:SYK
134.8B USD
Loading...
IE
Medtronic PLC
NYSE:MDT
129B USD
Loading...
US
Becton Dickinson and Co
NYSE:BDX
57B USD
Loading...
DE
Siemens Healthineers AG
XETRA:SHL
48.1B EUR
Loading...
US
IDEXX Laboratories Inc
NASDAQ:IDXX
55.7B USD
Loading...
US
Edwards Lifesciences Corp
NYSE:EW
48.6B USD
Loading...
US
Resmed Inc
NYSE:RMD
36.7B USD
Loading...

Market Distribution

Lower than 95% of companies in the United States of America
Percentile
5th
Based on 14 112 companies
5th percentile
-2 669.9%
Low
-4 087 900% — -5.1%
Typical Range
-5.1% — 14.8%
High
14.8% — 1 032 600%
Distribution Statistics
the United States of America
Min -4 087 900%
30th Percentile -5.1%
Median 6%
70th Percentile 14.8%
Max 1 032 600%

Orchestra Biomed Holdings Inc
Glance View

Market Cap
228.1m USD
Industry
Health Care

Orchestra Biomed Holdings, Inc. engages in the provision of biomedical technologies to patients through risk-reward-sharing partnerships with medical device companies. The company is headquartered in New Hope, Pennsylvania. The company went IPO on 2020-08-04. The company is engaged in developing technologies for patients through risk-reward sharing partnerships with medical device companies. Its flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) and Virtue Sirolimus AngioInfusion Balloon (SAB). BackBeat CNT is a bioelectronic treatment for hypertension that is designed to drive an immediate reduction in blood pressure while simultaneously modulating autonomic nervous system responses to maintain the reduction. Virtue SAB is a patented drug/device combination product candidate in development for the treatment of certain forms of artery disease that is designed to deliver an investigational, extended-release formulation of sirolimus, SirolimusEFR, to the vessel wall during balloon angioplasty without any coating on the balloon surface or the need to leave a stent or other permanent implant in the artery.

OBIO Intrinsic Value
Not Available
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-2 669.9%
=
Operating Income
$-75.2m
/
Revenue
$2.8m
What is Orchestra Biomed Holdings Inc's current Operating Margin?

The current Operating Margin for Orchestra Biomed Holdings Inc is -2 669.9%, which is below its 3-year median of -1 983%.

How has Operating Margin changed over time?

Over the last 3 years, Orchestra Biomed Holdings Inc’s Operating Margin has decreased from 153 750% to -2 669.9%. During this period, it reached a low of -2 857.4% on Jun 30, 2024 and a high of 153 750% on Aug 30, 2022.

Back to Top